Tenderwize
Back to tender search

Open-house rebate agreement for Roxithromycin

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 226 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Roxithromycin, ATC J01FA06

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

62 / 100

Complexity

58 / 100

Risk factors

The notice requires original submission and states that electronic submission is not allowed, which increases the risk...

Only authorised and marketable medicinal products in Germany are eligible, and additional AMIce/Lauer-Taxe evidence may...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Non-exclusive open-house rebate agreements for pharmaceutical products containing Roxithromycin (ATC J01FA06).
  • Supply of authorised and marketable medicinal products in Germany under uniform contract conditions.
Show full summary

Open-house supply arrangement for Roxithromycin (ATC J01FA06) pharmaceutical products by AOK Rheinland-Pfalz/Saarland. The notice states that interested pharmaceutical companies may join on equal terms, with no individual negotiations and no selection decision. The contract period runs from 01.06.2025 to 31.05.2027, with monthly entry possible, but the first submission deadline for the initial start date was 30.04.2025. No contract value is stated. The procedure is explicitly described as not constituting a public procurement contract under the procurement rules, although it is published in TED for transparency.

Risks

The notice requires original submission and states that electronic submission is not allowed, which increases the risk...

Only authorised and marketable medicinal products in Germany are eligible, and additional AMIce/Lauer-Taxe evidence may...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Only authorised and marketable medicinal products in Germany may be supplied.

Administrative

  • If a product is not listed in Lauer-Taxe at submission time, an AMIce public extract must be provided.
  • The AMIce extract must show product name, marketing authorisation holder or authorised manufacturer, dosage form, active substance, and marketability.

Buyer

Lots (1)

LOT-0001

Open-house rebate agreement for Roxithromycin

Single lot covering non-exclusive open-house rebate agreements for medicinal products containing Roxithromycin (ATC J01FA06). The scope excludes paediatric medicines listed in the BfArM list under Section 35(5a) SGB V. Contract terms are uniform for all participants; no individual negotiations are conducted. Contracts can start on the first day of a month within the 24-month period, with a maximum duration of 24 months from the earliest start date. The lot information is explicit in the structured data and notice text.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

May 2025 - May 2027

Category

Pharmaceutical products

Deadline

Deadline Mar 31, 2027

Procurement Details

Publication date
10 Apr 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
236088-2025

Documents (1)

Similar tenders